Perfood specialises in digital therapeutics that utilise personalised, low-glycaemic diets to prevent and treat glucose metabolism-related conditions, such as diabetes and migraines.

Using proprietary AI-driven algorithms, Perfood analyses continuous glucose monitoring (CGM) data, app diaries, and other wearable inputs to create customised dietary interventions. Their solutions have demonstrated robust clinical efficacy, such as a 63% reduction in migraine days.

With over 10,000 patients treated, 20+ clinical studies, and 8 peer-reviewed publications, Perfood's rigorous data-driven approach ensures significant impact. Their future pipeline includes therapeutic targets such as psoriasis, colon cancer, and osteoporosis, addressing the global healthcare needs of billions.